spacer
home > ebr > winter 2003 > is resistance futile?
PUBLICATIONS
European Biopharmaceutical Review

Is Resistance Futile?

Resistance is futile, or so the battle cry of the new enemy of humans in Star Trek goes. However resistance is hardly futile in the case of the retrovirus HIV. To date, HIV has infected 42 million people worldwide. In 2002 there were five million new infections and three million people died as a result of HIV infection or its end result - acquired immune deficiency syndrome (AIDS). The latest figures suggest that one person worldwide is infected with HIV every 60 seconds and 70 per cent of the burden of the world's HIV epidemic is carried by sub-Saharan Africa.

Since HIV-1 was isolated in 1984 and the cause of AIDS discovered, the innovation in drug development has been unrelenting. HIV infects and destroys human CD4 receptor positive cells in human hosts. This destruction leads to a loss of the cellular immune response and thus a switch of the immune system from a TH1 response to a TH2 one. The destruction of CD4+ cells is caused by the assembly of new HIV virus particles and their final budding out of the infected cell.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr DC Herath, Senior Medical Advisor in HIV at Roche UK

Dr DC Herath completed his Medical Degree at St Mary's Hospital Medical School, London. During that time, Dr Herath also completed a BSc in Haematology, conducting a study into thrombophilic disorders in recurrent miscarriage women. Having graduated, he spent several years as SHO in the major specialities (Renal, Neurology, Cardiology, Gastroenterology, Respiratory and ID/HIV) all at St Mary's, and then worked as SpR in HIV at St Mary's before moving to Roche as Clinical Science Specialist on the TORO 2 study in February 2002. In June of this year, Dr Herath undertook the post of Senior Medical Advisor in HIV for the Roche UK affiliate, overseeing the whole HIV portfolio from a medical viewpoint. He is still a practising physician in HIV, with a patient list of 80 at St Mary's Hospital in London.

spacer
Dr DC Herath
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement